17th annual bear stearns healthcare conference new york september 14 2004 forward looking statements this presentation may contain that reflect management s current views as to the company clinical trials regulatory approval process product development research programs and other future events operations these involve uncertainties risks are detailed in 1 registration statement filed with sec actual results could differ materially from overview investment thesis a platform technology yielding proprietary products offer significant advantages low technical risk short pathway facing timely market demand favorable climate conditionally bioreversible derivatives c within therapeutic window at high doses hydrolysis absorption fn dosage conjugate active illustrative elimination metabolism us adhd opportunity 0 500 000 2 3 2005 2006 2007 2008 2009 stimulant non total estimated cagr 2002 13 6 12 million potential customers
